Enzo Biochem INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Enzo Biochem, a life sciences company, reported a wider quarterly operating loss and a significant revenue decline for the three months ended April 30, 2025, while announcing a strategic review and its voluntary delisting from the NYSE to OTCQX.
Enzo Biochem's Q2 2025 revenue decreased by 14% year-over-year, driven by lower market demand and timing of large order fulfillment, as the company continues to explore strategic alternatives.
Enzo Biochem's first quarter of fiscal year 2025 saw a decrease in revenue and a net loss, impacted by reduced customer orders and market challenges.
Enzo Biochem's Q3 2024 results show increased product revenue and reduced losses compared to the same period last year, following the sale of its clinical services business.
10-Q: Enzo Biochem Reports Improved Revenue and Reduced Losses in Q2 2024 Following Clinical Lab Sale
Enzo Biochem saw a revenue increase and reduced losses in the second quarter of fiscal year 2024, primarily driven by growth in its product segment and the sale of its clinical lab business.